C. Kent Osborne
机构: Director/Professor, Duncan Cancer Center, Baylor College of Medicine
主页: bcm.edu
每年引用次数
引用次数
引用: 45,488
H-指数: 52
I10-指数 : 56
出版物: 59
Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice
K Hobbs , C K Osborne , G M Clark
Cancer Research 45 ( 2) 584 -590
396
1985
Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase
D H Boldt , G M Clark , J M Trent , C K Osborne
Cancer Research 43 ( 8) 3583 -3585
250
1983
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
J O'Sullivan , G M Clark , D C Allred , D Ciocca
Clinical Cancer Research 4 ( 1) 7 -12
256
1998
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.
G M Clark , G W Sledge , C K Osborne , W L McGuire
Journal of Clinical Oncology 5 ( 1) 55 -61
344
1987
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.
D C Allred , G M Clark , A K Tandon , R Molina
Journal of Clinical Oncology 10 ( 4) 599 -605
606
1992
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer.
G M Clark , C K Osborne , W L McGuire
Journal of Clinical Oncology 2 ( 10) 1102 -1109
485
1984
Growth Inhibition of Human Breast Cancer Cells in Vitro with an Antibody against the Type I Somatomedin Receptor
C. Kent Osborne , Carlos L. Arteaga
Cancer Research 49 ( 22) 6237 -6241
239
1989
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
Suleiman Massarweh , Rachel Schiff , C. Kent Osborne , Jiang Shou
Clinical Cancer Research 11 ( 2)
329
2005
Breast Cancer Endocrine Resistance How Growth Factor Signaling and Estrogen Receptor Coregulators Modulate Response
Suleiman Massarweh , Rachel Schiff , C. Kent Osborne , Jiang Shou
Clinical Cancer Research 9 ( 1)
440
2003
Transforming growth factor β: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells
Daniel D. Von Hoff , C. Kent Osborne , Carlos L. Arteaga , Atul K. Tandon
Cancer Research 48 ( 14) 3898 -3904
242
1988
Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use
C. Kent Osborne , Hong (Holly) Zhao , Suzanne A. W. Fuqua
Journal of Clinical Oncology 18 ( 17) 3172 -3186
323
2000
Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer
Jennet M. Harvey , Gary M. Clark , C. Kent Osborne , D. Craig Allred
Journal of Clinical Oncology 17 ( 5) 1474 -1474
2,415
1999
Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study.
Kathy S. Albain , Stephanie Green , Michael LeBlanc , Saul Rivkin
Breast Cancer Research and Treatment 22 ( 3) 273 -284
24
1992
Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase
M. Carolina Gutierrez , Simone Detre , Stephen Johnston , Syed K. Mohsin
Journal of Clinical Oncology 23 ( 11) 2469 -2476
393
2005
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
Grazia Arpino , Lisa Wiechmann , C. Kent Osborne , Rachel Schiff
Endocrine Reviews 29 ( 2) 217 -233
615
2008
Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients
Jan Grøndahl-Hansen , Susan G. Hilsenbeck , Carle Christensen , Gary M. Clark
Breast Cancer Research and Treatment 43 ( 2) 153 -163
48
1997
Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer.
Song Yao , William E. Barlow , Kathy S. Albain , Ji-Yeob Choi
Breast Cancer Research and Treatment 124 ( 2) 433 -439
24
2010
Molecular profiles of progesterone receptor loss in human breast tumors
Chad J. Creighton , C. Kent Osborne , Marc J. van de Vijver , John A. Foekens
Breast Cancer Research and Treatment 114 ( 2) 287 -299
85
2009
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.
Polly Niravath , Susan G. Hilsenbeck , Tao Wang , Sao Jiralerspong
Breast Cancer Research and Treatment 177 ( 2) 427 -435
3
2019
The value of estrogen and progesterone receptors in the treatment of breast cancer
C. Kent Osborne , Michael G. Yochmowitz , William A. Knight , William L. McGuire
Cancer 46 ( S12) 2884 -2888
965
1980